Our studies extend understanding of this oncoprotein by demonstrating UHRF1/UBE2L6/UBR4-mediated EZH2 promotion to enhance LPC phenotypes and disease progression in melanoma, providing a mechanism as to how higher levels of EZH2 are associated with late-stage disease. Here, UBR4 is linked to melanoma.